Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Otsuka Holdings Co., Ltd.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Otsuka Holdings Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Otsuka Holdings Co., Ltd. - The report provides overview of Otsuka Holdings Co., Ltd. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Otsuka Holdings Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Otsuka Holdings Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Otsuka Holdings Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Otsuka Holdings Co., Ltd. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Otsuka Holdings Co., Ltd.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Otsuka Holdings Co., Ltd. Snapshot 7 Otsuka Holdings Co., Ltd. Overview 7 Key Information 7 Key Facts 7 Otsuka Holdings Co., Ltd. - Research and Development Overview 8 Key Therapeutic Areas 8 Otsuka Holdings Co., Ltd. - Pipeline Review 12 Pipeline Products by Stage of Development 12 Pipeline Products - Monotherapy 13 Pipeline Products - Combination Treatment Modalities 14 Pipeline Products - Partnered Products 15 Partnered Products/Combination Treatment Modalities 16 Otsuka Holdings Co., Ltd. - Pipeline Products Glance 17 Otsuka Holdings Co., Ltd. - Late Stage Pipeline Products 17 Pre-Registration Products/Combination Treatment Modalities 17 Phase III Products/Combination Treatment Modalities 18 Otsuka Holdings Co., Ltd. - Clinical Stage Pipeline Products 19 Phase II Products/Combination Treatment Modalities 19 Phase I Products/Combination Treatment Modalities 20 Otsuka Holdings Co., Ltd. - Early Stage Pipeline Products 21 Preclinical Products/Combination Treatment Modalities 21 Otsuka Holdings Co., Ltd. - Drug Profiles 22 (carteolol hydrochloride + latanoprost) 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 (tipiracil hydrochloride + trifluridine) 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 levetiracetam 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 ponatinib hydrochloride 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 tolvaptan 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 (aripiprazole + sertraline) 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 (gimeracil + oteracil + tegafur) 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 aripiprazole ER 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 AVP-786 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 brexpiprazole 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 delamanid 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 nabiximols 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 rebamipide 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 (dextromethorphan + quinidine sulfate) 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 OCV-501 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 OPA-15406 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 OPS-2071 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 probucol 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 tetomilast 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 OPA-6566 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 OPB-111001 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 LPC-01 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 LUAF-20513 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 OCVC-02 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 OPB-111077 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 OPC-108459 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 OPC-39436 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 OPC-64005 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 OPC-28326 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Otsuka Holdings Co., Ltd. - Pipeline Analysis 71 Otsuka Holdings Co., Ltd. - Pipeline Products by Target 71 Otsuka Holdings Co., Ltd. - Pipeline Products by Route of Administration 73 Otsuka Holdings Co., Ltd. - Pipeline Products by Molecule Type 74 Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action 75 Otsuka Holdings Co., Ltd. - Recent Pipeline Updates 77 Otsuka Holdings Co., Ltd. - Dormant Projects 113 Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products 114 Discontinued Pipeline Product Profiles 114 (gimeracil + oteracil + tegafur) 114 (tipiracil hydrochloride + trifluridine) 114 AVP-13358 114 AZD-2479 115 brexpiprazole 115 dasatinib 115 OCV-101 115 OPB-31121 115 OPB-51602 115 rebamipide 115 Otsuka Holdings Co., Ltd. - Company Statement 117 Otsuka Holdings Co., Ltd. - Locations And Subsidiaries 118 Head Office 118 Other Locations & Subsidiaries 118 Appendix 121 Methodology 121 Coverage 121 Secondary Research 121 Primary Research 121 Expert Panel Validation 121 Contact Us 121 Disclaimer 122
List of Tables
Otsuka Holdings Co., Ltd., Key Information 7 Otsuka Holdings Co., Ltd., Key Facts 7 Otsuka Holdings Co., Ltd. - Pipeline by Indication, 2016 9 Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2016 12 Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2016 13 Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016 14 Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2016 15 Otsuka Holdings Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2016 16 Otsuka Holdings Co., Ltd. - Pre-Registration, 2016 17 Otsuka Holdings Co., Ltd. - Phase III, 2016 18 Otsuka Holdings Co., Ltd. - Phase II, 2016 19 Otsuka Holdings Co., Ltd. - Phase I, 2016 20 Otsuka Holdings Co., Ltd. - Preclinical, 2016 21 Otsuka Holdings Co., Ltd. - Pipeline by Target, 2016 71 Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2016 73 Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2016 74 Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action, 2016 75 Otsuka Holdings Co., Ltd. - Recent Pipeline Updates, 2016 77 Otsuka Holdings Co., Ltd. - Dormant Developmental Projects,2016 113 Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products, 2016 114 Otsuka Holdings Co., Ltd., Other Locations 118 Otsuka Holdings Co., Ltd., Subsidiaries 118
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Global advanced energy storage systems market size is anticipated to be valued at USD 24.8 billion by 2022, as per a new research report by Radiant Insights, Inc. Increasing energy consumption coupled with strong energy demand for industrial, commercRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.